◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Aurobindo Pharma Limited (AUROPHARMA) EPS 2023–2026

Name: Aurobindo Pharma Limited (AUROPHARMA) eps history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Aurobindo Pharma Limited annual earnings per share (EPS) for fiscal 2026 was ₹60.34, an increase of 0.9% from ₹59.81 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

AUROPHARMA Annual EPS

EPS (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Diluted EPS	₹60M	₹60M	₹54M	₹33M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUROPHARMA Quarterly EPS

EPS (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Diluted EPS	₹18M	₹16M	₹16M	₹14M	₹16M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

4151 EPS — Kyowa Kirin Co., Ltd.
ZYDUSLIFE EPS — Zydus Lifesciences Limited
CIPLA EPS — Cipla Limited
LAURUSLABS EPS — Laurus Labs Limited
DRREDDY EPS — Dr. Reddy's Laboratories Limited
LUPIN EPS — Lupin Limited

More AUROPHARMA metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All AUROPHARMA financial statements → Interactive AUROPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.